Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Cardiovascular-Kidney-Metabolic (CKM) syndrome is a recently proposed framework that captures the interconnected pathophysiology of cardiovascular, kidney, and metabolic diseases. While these conditions share common risk factors with cancer, the association between CKM stage and cancer incidence remains unclear. We aimed to investigate this relationship in a large-scale, real-world Japanese population.
We conducted a retrospective cohort study using the nationwide administrative claims database (2014–2023), which integrates health checkup and insurance claims data. Individuals with prior cancer or missing covariates were excluded. A total of 1,390,901 participants were classified into CKM stages 0–4 according to the 2023 American Heart Association statement, incorporating cardiometabolic risk factors, chronic kidney disease, and atherosclerotic cardiovascular disease. The primary outcome was incident cancer, defined by ICD-10 codes C00–C97. Cox proportional hazards models estimated hazard ratios (HRs) with 95% confidence intervals (CIs), adjusting for demographic, clinical, and lifestyle factors. Subgroup analyses by age and sex and multiple sensitivity analyses using alternative CKM definitions were performed.
Over a median follow-up of 3.4 years, the incidence of cancer clearly differed by CKM stage, with particularly higher rates observed in Stages 3 and 4. Adjusted HRs (95% CI) compared with Stage 0 were: 1.03 (0.99–1.08) for Stage 1, 1.02 (0.99–1.05) for Stage 2, 1.25 (1.21–1.29) for Stage 3, and 1.30 (1.25–1.35) for Stage 4. The dose–response association was consistent across cancer types, including colorectal, lung, stomach, liver, kidney, and bladder cancers, and was particularly strong among men and individuals aged <65 years (P for interaction <0.001 for both). Sensitivity analyses using the Suita Score, Hisayama Risk Score, PREVENT equations, and alternative CVD definitions confirmed the robustness of the findings.
Advancing CKM stage was significantly associated with increased risk of incident cancer in this nationwide cohort. These findings expand the clinical relevance of the CKM framework beyond cardiovascular and kidney outcomes to oncologic risk, underscoring the need for integrated risk stratification and prevention strategies in multimorbid populations. Incorporating cancer prevention into CKM management may improve long-term health outcomes and guide multidisciplinary approaches in clinical practice.
